Scientists Successfully Remove SIV from Non-Human Primates Using Breakthrough Gene Editing Technology
Groundbreaking Research Conducted at Temple University’s Lewis Katz School of Medicine Marks Significant Progress in HIV Treatment
A team of scientists from the prestigious Lewis Katz School of Medicine at Temple University in the United States has made an astounding breakthrough in the field of human HIV treatment. Their recently published study in the esteemed journal Gene Therapy details the successful removal of the simian immunodeficiency virus (SIV) from the genetic makeup of non-human primates, using a cutting-edge gene editing technology known as EBT-001.
This remarkable preclinical research utilizing CRISPR-Cas9 gene editing technology is considered a major step forward in combating HIV. Rhesus monkeys were selected as the subjects for this study, and the scientists employed the highly targeted gene editing tool EBT-001, specifically designed to identify and remove the proviral DNA of SIV with utmost precision.
Extensive studies have demonstrated the safety and effectiveness of EBT-001 in removing latent SIV from the virus reservoir within the host DNA, with absolutely no off-target effects observed in animals. The ultimate objective of this groundbreaking technology is to permanently eradicate the virus in large animal model tissues through a single injection treatment, thereby achieving a significant breakthrough in the fight against HIV.
For the experiment, the researchers utilized non-human primates as their preclinical test subjects. They skillfully integrated the SIV-specific CRISPR-Cas9 (EBT-001) gene editing construct into an adeno-associated virus 9 (AAV9) vector, which was then intravenously injected into the SIV-infected animals. This innovative method showcases the immense potential of gene editing therapies for not only HIV but also other infectious diseases such as herpes simplex virus and hepatitis B.
With this groundbreaking achievement, the path is paved for further clinical trials of EBT-101, further bolstering prospects for the treatment and prevention of HIV. Moreover, this notable milestone in HIV research injects newfound hope into the development of multiple gene editing therapies, promising a brighter future for countless individuals plagued by infectious diseases.
Recently, news broke that scientists from the Lewis Katz School of Medicine at Temple University in the US have used EBT-001, a CRISPR-Cas9 gene editing technology, to successfully remove SIV (simian immunodeficiency virus) from the genome of non-human primates . safe and efficient. .
The preclinical research, which marks an important step in the field of human HIV treatment, has been published online in the journal Gene Therapy.
In this study, the research team chose rhesus monkeys as test subjects and used a CRISPR-Cas9 gene editing tool called EBT-001, which can precisely locate the SIV proviral DNA.
Studies have shown that EBT-001 can safely and efficiently remove latent SIV in the virus reservoir from the host DNA, and there is no off-target effect in animals.
The aim of this new technology is to permanently clear the virus in large animal model tissues through a one-time injection treatment. The results of this study confirm the safety of this technology.
Scientists used non-human primates as preclinical test subjects, edited the SIV-specific CRISPR-Cas9 (EBT-001) gene editing construct into an adeno-associated virus 9 (AAV9) vector, and injected it intravenously into SIV infected animals.
This breakthrough provides an important direction for the ongoing clinical trials of EBT-101. This is not only an important milestone in HIV research, but also injects power into the development of multiple gene editing therapies for herpes simplex virus, hepatitis B and other infectious diseases.
#Major #breakthrough #gene #editing #HIV #cleared #shot #Qooah
